ADVERTISEMENT
Press release content from Business Wire. The AP news staff was not involved in its creation.
Related topics
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Sangamo Therapeutics Announces Third Quarter 2021 Conference Call and Webcast

October 28, 2021 GMT

BRISBANE, Calif.--(BUSINESS WIRE)--Oct 28, 2021--

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the Company has scheduled the release of its third quarter 2021 financial results on Thursday, November 4, 2021. The press release will be followed by a conference call at 9:15 a.m. ET, which will be open to the public via telephone and webcast. During the conference call, the Company will review its financial results and provide business and clinical updates.

The conference call dial-in numbers are (877) 377-7553 for domestic callers and (678) 894-3968 for international callers. The conference ID number for the call is 5178059. Participants may access the live webcast via a link on the Sangamo Therapeutics website in the Investors and Media section under Events and Presentations. A conference call replay will be available for one week following the conference call. The conference call replay numbers for domestic and international callers are (855) 859-2056 and (404) 537-3406, respectively. The conference ID number for the replay is 5178059.

ADVERTISEMENT

About Sangamo Therapeutics

Sangamo Therapeutics is a clinical-stage biopharmaceutical company with a robust genomic medicines pipeline. Using ground-breaking science, including our proprietary zinc finger genome engineering technology and manufacturing expertise, Sangamo aims to create new genomic medicines for patients suffering from diseases for which existing treatment options are inadequate or currently don’t exist. For more information about Sangamo, visit www.sangamo.com.

View source version on businesswire.com:https://www.businesswire.com/news/home/20211028005261/en/

CONTACT: Investor & Media Inquiries

Aron Feingold

628-252-7494

afeingold@sangamo.com

KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA

INDUSTRY KEYWORD: BIOTECHNOLOGY PHARMACEUTICAL GENETICS HEALTH

SOURCE: Sangamo Therapeutics, Inc.

Copyright Business Wire 2021.

PUB: 10/28/2021 04:30 PM/DISC: 10/28/2021 04:32 PM

http://www.businesswire.com/news/home/20211028005261/en